CA2444370A1 - Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders - Google Patents
Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders Download PDFInfo
- Publication number
- CA2444370A1 CA2444370A1 CA002444370A CA2444370A CA2444370A1 CA 2444370 A1 CA2444370 A1 CA 2444370A1 CA 002444370 A CA002444370 A CA 002444370A CA 2444370 A CA2444370 A CA 2444370A CA 2444370 A1 CA2444370 A1 CA 2444370A1
- Authority
- CA
- Canada
- Prior art keywords
- microcirculation disorders
- disease
- substance
- microcirculation
- dipyridamole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A method of treatment of the human or non-human animal body for treating NO- dependent microcirculation disorders is disclosed, for example microcirculation disorders caused by metabolic diseases, such as elevated levels of homocystin-homocystein inflammatory reactions or autoimmune diseases, furthermore peripheral microcirculation disorders or microcirculation disorders associated with increased cell fragmentation, whi ch method comprises administering to a human or non-human animal body in need o f such treatment an effective amount of a pharmaceutical composition containin g a substance which scavenges free radicals, e.g. a pyrimido-pyrimidine select ed from Dipyridamole, Mopidamol and the pharmaceutically acceptable salts thereof, and the use such substance for the manufacture of a corresponding pharmaceutical composition, optionally in combination with an agent capable of increasing NO production, more particularly HMG-CoA reductase inhibitors suc h as aspirin.
Description
Use of Radical scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders Field of the Invention This invention relates to a method of treatment of disorders of the microcirculation, particularly those where insufficient generation of NO seems to be the cause of the problem, using substances to scavange free radicals such as Dipyridamole or Mopidamol in doses lower than those needed to directly inhibit platelet aggregation alone or in combination with substance to increase cellular Nitric oxide (NO) production such as HMG CoA
reductase inhibitors at doses below the typical dose to lower serum lipids but sufficient to still enhance eNOS in cells of the vasculature.
Background of the Invention By laboratory models reflecting the complex physiology of the blood vessel it could be shown that the vasculature is not a passive conduit, but interacts profoundly with the blood through an intricate system of checks and balances to protect its integrity after vascular accident. Therefore the endo-thelium produces prostacyclin, a potent inhibitor of aggre-gation. The normal endothelium is not thrombogenic and pre-vents the attachment of platelets. Various stimulants preci-pitate the release of endothelium-derived relaxing factor (EDRF), which inhibits platelet adhesion and aggregation. At the same time, intracellular increase in cGMP was shown to be responsible for.relaxation of smooth muscle cells following administration of nitro compounds. Thus the endothelium can provide maintenance of local perfusion of the vessels by several separate mechanisms, one being the local vasodilata-tion mediated by prostacyclin and Nitric Oxide (N0, also described in literature as EDRF) and another being the decreased interaction of blood cells with each other or the negative interaction of white blood cells or blood platelets with the cells of the vessel wall. Another would be the con-trol of local fibrin accumulation by controlling the formation as well as lysis of already formed strands of fibrin. In larger vessels aggregation and adhesion of platelets to damaged parts of the vessel wall particularly after interven-tional therapy play an important role and have been shown to be treated with inhibitors of platelet aggregation (see WO
98/11896). The benefit of enhancing endothelial NO synthesis by HMG CoA reductase inhibitors has been described in US Pa-tent No. 5,968,983 and WO 00/56403.
In the past prevention and treatment of conditions causing reduced tissue perfusion have been focussed mainly on mecha-nical as well as pharmaceutical re-vasularisation of the larger arteries supplying blood to a larger area of tissue.
The focus did lay on either preventing build-up of athero-sclerotic plaques (lipid lowering therapy) or on the preven-tion of the thromboembolic occlusion triggered by rupturing plaque and activation of platelet aggregation leading often to an occlusive thrombus. This is the reason why major efforts have been focussed on inhibition of aggregation of platelets, ultimately by blocking the final common pathway of platelet aggregation, i.e. by inhibiting the receptor for fibrinogen on platelets, the final step of linking platelets together when forming a_platelet rich thrombus. It therefore is also straight forward to combine lipid lowering therapy with potent platelet aggregation inhibitors of combinations of such as tought .in WO 98/11896.
In addition, procedures for fast and safe revascularisation of the occluded arteries have been developed such as pharmacolo-gical lysis of thrombi with thrombolytic agents such as r-tPA
or mechanically by transcutaneous intravascular balloon angio-plasty. Again here the major problem remaining is the acute rethrombosis of the reopened segment of the blood vessel, where strong inhibitors of platelet aggregation or the combi-nation of platelet inhibition with inhibitors of fibrin forma-tion have shown to be effective.
In preventing reoccurence of myocardial infarcts (MI), chronic application of mild platelet inhibitors such as Aspirin have shown only limited efficacy (published meta analysis aggree to a reduction of the incidence by 18 %). Using more potent pla-telet inhibitors such as various orally available inhibitors of the platelet fibrinogen receptor however have shown no improvement over the effect achieved by ASA. More than 37,000 patients have been subjects in major studies on the long term benefit of chronic administration of oral fibrinogen receptor antagonists in preventing cardiovascular events. All studies have been negative, in fact the treatment arm showed a higher risk for bleeding and increased mortality.
This concludes that long term benefit can not be extrapolated from the clear short term benefit of very strong inhibition of platelet aggregation even when combined with therapy designed to reduce the build up of atherosclerotic plaques or the elevated risk related to elevated levels of plasma lipids as done by lipid lowering therapy.
reductase inhibitors at doses below the typical dose to lower serum lipids but sufficient to still enhance eNOS in cells of the vasculature.
Background of the Invention By laboratory models reflecting the complex physiology of the blood vessel it could be shown that the vasculature is not a passive conduit, but interacts profoundly with the blood through an intricate system of checks and balances to protect its integrity after vascular accident. Therefore the endo-thelium produces prostacyclin, a potent inhibitor of aggre-gation. The normal endothelium is not thrombogenic and pre-vents the attachment of platelets. Various stimulants preci-pitate the release of endothelium-derived relaxing factor (EDRF), which inhibits platelet adhesion and aggregation. At the same time, intracellular increase in cGMP was shown to be responsible for.relaxation of smooth muscle cells following administration of nitro compounds. Thus the endothelium can provide maintenance of local perfusion of the vessels by several separate mechanisms, one being the local vasodilata-tion mediated by prostacyclin and Nitric Oxide (N0, also described in literature as EDRF) and another being the decreased interaction of blood cells with each other or the negative interaction of white blood cells or blood platelets with the cells of the vessel wall. Another would be the con-trol of local fibrin accumulation by controlling the formation as well as lysis of already formed strands of fibrin. In larger vessels aggregation and adhesion of platelets to damaged parts of the vessel wall particularly after interven-tional therapy play an important role and have been shown to be treated with inhibitors of platelet aggregation (see WO
98/11896). The benefit of enhancing endothelial NO synthesis by HMG CoA reductase inhibitors has been described in US Pa-tent No. 5,968,983 and WO 00/56403.
In the past prevention and treatment of conditions causing reduced tissue perfusion have been focussed mainly on mecha-nical as well as pharmaceutical re-vasularisation of the larger arteries supplying blood to a larger area of tissue.
The focus did lay on either preventing build-up of athero-sclerotic plaques (lipid lowering therapy) or on the preven-tion of the thromboembolic occlusion triggered by rupturing plaque and activation of platelet aggregation leading often to an occlusive thrombus. This is the reason why major efforts have been focussed on inhibition of aggregation of platelets, ultimately by blocking the final common pathway of platelet aggregation, i.e. by inhibiting the receptor for fibrinogen on platelets, the final step of linking platelets together when forming a_platelet rich thrombus. It therefore is also straight forward to combine lipid lowering therapy with potent platelet aggregation inhibitors of combinations of such as tought .in WO 98/11896.
In addition, procedures for fast and safe revascularisation of the occluded arteries have been developed such as pharmacolo-gical lysis of thrombi with thrombolytic agents such as r-tPA
or mechanically by transcutaneous intravascular balloon angio-plasty. Again here the major problem remaining is the acute rethrombosis of the reopened segment of the blood vessel, where strong inhibitors of platelet aggregation or the combi-nation of platelet inhibition with inhibitors of fibrin forma-tion have shown to be effective.
In preventing reoccurence of myocardial infarcts (MI), chronic application of mild platelet inhibitors such as Aspirin have shown only limited efficacy (published meta analysis aggree to a reduction of the incidence by 18 %). Using more potent pla-telet inhibitors such as various orally available inhibitors of the platelet fibrinogen receptor however have shown no improvement over the effect achieved by ASA. More than 37,000 patients have been subjects in major studies on the long term benefit of chronic administration of oral fibrinogen receptor antagonists in preventing cardiovascular events. All studies have been negative, in fact the treatment arm showed a higher risk for bleeding and increased mortality.
This concludes that long term benefit can not be extrapolated from the clear short term benefit of very strong inhibition of platelet aggregation even when combined with therapy designed to reduce the build up of atherosclerotic plaques or the elevated risk related to elevated levels of plasma lipids as done by lipid lowering therapy.
Description of the Invention Tissue perfusion is vital to the health and survival and func-tion of any organ, particularly those organs with high oxygen and nutritive demand. Even after successful revascularisation of epicardial arteries the perfusion of the tissue, i.e. the properties of the microcirculation have been shown to signi-ficantly influence the mortality after MI at 90 days (Gibbson at all, Circulation 2000, 101:125-130), resulting in a reduc-tion of mortality from 4.6% to 0.8%, in cases where tissue perfusion, was not reduced, i.e. microcirculation was not compromised.
This present invention focuses on the importance of tissue perfusion on the level of smaller vessels downstream of the large vessels, supplying tissue with oxygen and nutrients by improving microcirculation. Microcirculation disorders, i.e.
circulation disorders caused by microvascular dysfunction, can be caused by metabolic or oxidative stress leading to diseases where vascular dysfunction or damages are involved.
The present invention provides a new approach for improving microcirculation by treatment and/or prevention of such dis-orders of microcirculation which are caused by reduced endo-genous NO production by cells otherwise needed for local pre-vention of vessel spasm or loss of dilatory reactivity as well as prevention of cell mediated damage. The improvement of NO-dependent microvascular dysfunction is especially important in small vessels or capillary vessels where the ratio of vessel wall surface area to blood volume is high, and provides a new approach for treatment and prevention of disorders of the NO.
Therefore, radical scavengers like Dipyridamole and Mopidamol alone or in combination with substance capable of increasing NO production may have therapeutic potential in a variety of diseases involving progressive dysfunction of medium and small-sized vessels.
Accordingly, disorders of the microcirculation according to the present invention are meant to be those where by metabolic or genetic influence the cells of the vasculature are no longer able to produce sufficient amount of NO, the potent local regulator of homeostasis in the vascular system. Such disorders are named herein "NO-dependent microcirculation disorders". Examples of such disorders are diabetic angiopathy, especially diabetic microangiopathy, e.g.
diabetic gangrene, diabetic retinopathy, diabetic neuropathy, or such as hyperhomocysteinemia, homocysteinuria, pulmonary hypertension, mucoviscidosis, neuro-degenerative disease, ulcus cruris, atrophic gastritis, colitis ulcerosa, or microcirculation disorders occuring after partial resection of stomach and / or bowels;
furthermore re-establishment of blood flow upon insufficient tissue perfusion after revascularisation of large arteries such as after acute MI or Stroke or in peripheral artery disease in addition or following acute antiplatelet therapy to prevent acute reocclusion, e.g. ~as disclosed in WO 98/11896;
similarly conditions where dysfunction is caused by re-perfusion injury after revascularisation or in transplant recipient;
microcirculation disorders caused by inflammatory reactions, such as morbus crohn, colitis ulcerosa or acute respiratory dystress syndrome CARDS);
microcirculation disorders caused by autoimmune diseases, such as autoimmune chronic-active hepatitis (idiopathic hepatitis), primary-biliary cirrhosis or (autoimmune associated) multiple sclerosis;
peripheral microcirculation disorders, such as Raynaud's disease, tinnitus or sudden loss of hearing;
microcirculation disorders associated with increased cell fragmentation, such as tumor diseases or thrombotic-thrombocytopenic purpura (TTP) ;
and nephrosclerosis, prerenal hypertension, haemolytic-uremic syndrome (HUS), arterial hypertension, vascular dementia, Alzheimer's disease, Sudeck's disease, central-veneous thrombosis of the eye, ischemic optic neuropathy, homocystine-induced vasculopathy, ischemic or coronary heart diseases, prevention of myocardial infarction or reinfarction, ... treatment or prevention of atherosclerosis, degenerative diseases of joints such as arthritis.
The indication "NO-dependent microcirculation disorders"
further includes corresponding disorders of the myocardium.
Thus the present invention provides a method for improving the blood supply of the myocardium in a person in need of such treatment, for example in a person suffering from ischemic or coronary heart disease, as well as a method for prevention of myocardial infarction or re-infarction. This in particular after successful reperfusion by mechanical or pharmacological revascularisation and in parallel or after the inhibition of acute rethrombosis / reocclusion by strong inhibitors of platelet aggregation.
Furthermore, treatment of "NO-dependent microcirculation disorders" within the present invention also includes treat-ment or prevention of atherosclerosis by improving perfusion through the vasa vasorum of large vessels.
NO-dependent disorders of the microcirculation can be ap-proached by either increasing the local production of NO or, preferably, by combining the increase of NO with reducing the local destruction of NO.
Preferred is pulmonary hypertension; re-establishment of blood flow upon insufficient tissue perfusion after revascularisa-tion of large arteries such as after acute MI or Stroke or in peripheral artery disease in addition or following acute anti-platelet therapy to prevent acute reocclusion, e.g. as disclo-sed in WO 98/11896; conditions where dysfunction is caused by re-perfusion injury after revasularisation or in transplant recipient; peripheral microcirculation disorders, such as Raynaud's disease, tinnitus or sudden loss of hearing;
_ g -vascular dementia, Alzheimer's disease; homocysteinuria and homocystine-induced vasculopathy;
ischemic or coronary heart diseases; prevention of myocardial infarction or reinfarction; and treatment or prevention of atherosclerosis.
Most preferred indication to be treated according to the present invention is insufficient tissue perfusion after revascularisation of large arteries such as after acute MI or Stroke or re-establishment of blood flow in peripheral artery disease in addition or following acute antiplatelet therapy to prevent acute reocclusion; homocysteinuria and homocystine-induced vasculopathy; and vascular dementia.
It is found that a substance which scavenges free radicals increases the local production of NO. Accordingly, NO-depen-dent microcirculation disorders can be treated according to the present invention by a method of treatment comprising a substance which scavenges free radicals.
Preferred is a substance that scavenges free oxy- and / or peroxi- radicals.
Further preferred is a substance that is membrane bound and scavenges oxy- and peroxy radicals.
Compounds acting as scavengers according to the present invention are, for example, Probucol, Ascorbic acid, Alpha tocopherol, _ g _ Dipyridamole or Mopidamol;
preferred is Dipyridamole and Mopidamol;
most preferred is Dipyridamole.
A said substance is applied optionally in combination with an agent capable of increasing NO production. A compound capable to increase NO production according to the present invention is, for example, Acetylcholine estrogen, or HMG CoA reductase inhibitors such as Lovastatin, Pravastatin, Simvastatin, Fluvastatin, Dalvastatin, Compactin, Mevastatin, HR 780, BMY 22,089, BMY 22,566, SQ 33,600, GR 95,030 or CI 981;
preferred is Lovastatin, Pravastatin, Simvastatin, Fluvastatin, Dalvastatin, Compactin, Mevastatin, HR 780, BMY 22,089, BMY 22,566, SQ 33,600, GR 95,030 or CI 981;
more preferred is Lovastatin, Pravastatin, Simvastatin, Fluvastatin, Dalvastatin, Compactin, Mevastatin.
Preferred is the combination of Mopidamol or even more prefer-red Dipyridamole with an agent selected from the class of HMG
CoA reductase inhibitors. The combination of sub-/or thera-peutical doses of HMG CoA reductase inhibitors known to upre-gulate expression of eNOS (endothelial nitric oxide synthe-tase), which have clinical benefit at lipid lowering doses, with doses of Dipyridamole or Mopidamol, which inhibits destruction of NO.
If the substance which scavenges free radicals is chosen as Dipyridamole or Mopidamol it is of advantage to maintain a plasma level of Dipyridamole or Mopidamol of about 0.2 to 5 umol/L, preferably of about 0.4 to 5 ~mol/L, especially of about 0.5 to 2 umol/L or particularly of about 0.8 to 1.5 umol/L or when combined with HMO CoA reductase inhibitors at 0.2 to 2.0 umol/L. This can be achieved using any of the oral Dipyridamole retard, instant or the parenteral formulations on the market, the retard formulations being preferred, for instance those available under the trademark Persantin°, or, for an optional additional combination therapy with low-dose acetyl salicylic acid (ASA), using those formulations avail-able under the trademark Asasantin° or Aggrenox°. Dipyridamole retard formulations are also disclosed in EP-A-0032562, instant formulations are disclosed in EP-A-0068191 and combinations of ASA with Dipyridamole are disclosed in EP-A-0257344 which are incorporated by reference. In case of Mopidamol also oral retard, instant or a parenteral formu-lations can be used, e.g. those disclosed in GB 1,051,218 or EP-A-0,108,898 which are incorporated by reference, retard formulations being preferred.
Dipyridamole or Mopidamol can be administered orally in a daily dosage of 25 to 450 mg, preferably 50 to 240 mg, most preferred 75 to 200 mg. For long-term treatment it is of advantage to administer repeated doses such as a dose of 25 mg Dipyridamole retard or any other instant release formulation three or four times a day. For parenteral administration Dipy-ridamole could be given in a dosage of 0.5 to 5 mg/kg body weight, preferably 1 to 3.5 mg/kg body weight, during 24 hours as slow i.v. infusion (not faster than 0.2 mg/min).
Dipyridamole {2,6-bis(diethanolamino)-4,8-dipiperidino-pyri-mido[5,'4-d]pyrimidine~, closely related substituted pyrimido-pyrimidines and their preparation have been described in e.g.
U.S. Patent 3,031,450. Further related substituted pyrimido-pyrimidines and their preparation have been described in e.g.
GB 1,051,218, inter alia the compound Mopidamol (2,6-bis-(diethanolamino)-4-piperidinopyrimido[5,4-d]pyrimidine}.
Dipyridamole was introduced as a coronary vasodilator in the early 1960s. It is also well known having platelet aggregation inhibitor properties due to the inhibition of adenosine up-take. However, at doses above the dose range and therapeutically in the Aggrenox~ preparation. Whereas the activity of Dipyridamole and Mopidamol as platelet aggregation inhibitor directly in high concentrations and indirectly through the inhibition of Adenosine reuptake at therapeutic plasma levels is well known it is a new finding that these agents additionally are inhibitors of NO destruction mediated by their capacity to scavange oxi- as well as peroxi radicals while being bound to membranes of cells of the vessel wall.
Previous investigations led to its use as an antithrombotic agent; it soon became the therapy of choice for such applica-tions as stroke prevention, maintaining the patency of corona-ry bypass and valve-replacement, as well as for treatment prior to coronary angioplasty.
Furthermore, the European Stroke Prevention Study 2 (ESPS-2;
J Neurol Sci. 1996; 143: 1-13; Neurology 1998; 51: 17-19) proved that treatment by Dipyridamole alone was as effective as low-dose aspirin in the reduction of stroke risk, and combination therapy with Dipyridamole and aspirin was more than twice as effective as aspirin alone.
Dipyridamole appears to inhibit thrombosis through multiple mechanisms. Early studies showed that it inhibits the uptake of adenosine, which was found to be a potent endogenous anti-thrombotic compound. Dipyridamole was also shown to inhibit cyclic AMP phosphodiesterase, thereby increasing intracellular c-AMP.
Dipyridamole appears to enhance of above-mentioned antithrom-botic mechanisms (CAMP - increase, cGMP- increase) of the vessel wall, in addition to its adenosine-sparing effects. It stimulates prostacyclin production by increasing intracellular levels of cAMP, and it enhances the strongly nitric oxide system by increasing cGMP. It further prevents local fibrin formation.
Dipyridamole also has antioxidant properties (Free Radic.
Biol. Med. 1995; 18: 239-247) that may contribute to its antiatherosclerotic effect. When oxidized, low density lipo-proteins become recognized by the scavenger receptor on macro-phages, which is assumed to be the necessary step in the deve-lopment of atherosclerosis (Ann. Rev. Med. 1992; 43: 219-25).
Dipyridamole has been found to inhibit fibrinogenesis in experimental liver fibrosis (Hepatology 1996; 24: 855-864) and to suppress oxygen radicals and ~proteinuria in experimental animals with aminonucleoside nephropathy (Eur. J. Clin.
Invest. 1998; 28: 877-883; Renal Physiol. 1984; 7: 218-226).
Inhibition of lipid peroxidation also has been observed in human nonneoplastic lung tissue (Gen. Pharmacol. 1996; 27:
855-859) .
Viewed from one aspect the present invention provides a method of treatment of the human or non-human animal body, preferably mammalian body, for treating or preventing NO-dependent micro-circulation disorders or of disease states where such micro-circulation disorders are involved, said method comprising administering to said body an effective amount of a phar-maceutical composition comprising a substance with scavenges fre radicals, according to the invention, optionally in combi-nation with one or more agents capable of increasing NO pro-duction.
A preferred aspect the present invention provides the use of a pyrimido-pyrimidine selected from Dipyridamole, Mopidamol and the pharmaceutically acceptable salts thereof, Dipyridamole being preferred, optionally in combination with one or more agents capable of increasing NO production, preferably selec-ted form the class of HMG CoA-reductase inhibitors, for the manufacture of a pharmaceutical composition for the treatment of the human or non-human animal body, preferably mammalian body, for treating or preventing NO-dependent microcirculation disorders or of disease states where such microcirculation disorders are involved.
Examples Experimentally this condition is tested in animal models show-ing deficiency of microcirculatory function. Animal models used are experimental stroke models in rats and mice as well as in non-rodent animals including non-human primates.
In the stroke models the size of tissue damage after occlusion of an artery feeding a well defined area of the brain tissue is evaluated by histology and non-invasive imaging, measuring the extent of regional perfusion and tissue damage (MRI, CT).
The size of the infarcted tissue is found to be dependent on the capacity of the microcirculatory system to provide blood flow in the periphery under conditions of oxidative and meta-bolic stress. The size of the infarcted tissue is smaller after treatment with a combination of Dipyridamole and pra-vastatin. The same effect can be shown with other agents selected from the class of HMG CoA reductase inhibitors.
Further experiments are carried out with another animal model:
genetically engineered NO Synthetase knock-out mice are used where NO synthetase activity is blocked or partially inhibi-ted, respectively. By employing experimental conditions in such a model under which the NO Synthetase activity is blocked or reduced the effect of Dipyridamole in preventing NO de-struction is investigated and compared with the influence of pravastatin on elevating NO production. Thereby the effect of NO sparing is seen as independent effect in cases were incre-ase of NO production is limited.
The testing in animal models and subsequently in clinical trials with volunteers and patients includes testing of the efficacious dose range according to good clinical practice.
This present invention focuses on the importance of tissue perfusion on the level of smaller vessels downstream of the large vessels, supplying tissue with oxygen and nutrients by improving microcirculation. Microcirculation disorders, i.e.
circulation disorders caused by microvascular dysfunction, can be caused by metabolic or oxidative stress leading to diseases where vascular dysfunction or damages are involved.
The present invention provides a new approach for improving microcirculation by treatment and/or prevention of such dis-orders of microcirculation which are caused by reduced endo-genous NO production by cells otherwise needed for local pre-vention of vessel spasm or loss of dilatory reactivity as well as prevention of cell mediated damage. The improvement of NO-dependent microvascular dysfunction is especially important in small vessels or capillary vessels where the ratio of vessel wall surface area to blood volume is high, and provides a new approach for treatment and prevention of disorders of the NO.
Therefore, radical scavengers like Dipyridamole and Mopidamol alone or in combination with substance capable of increasing NO production may have therapeutic potential in a variety of diseases involving progressive dysfunction of medium and small-sized vessels.
Accordingly, disorders of the microcirculation according to the present invention are meant to be those where by metabolic or genetic influence the cells of the vasculature are no longer able to produce sufficient amount of NO, the potent local regulator of homeostasis in the vascular system. Such disorders are named herein "NO-dependent microcirculation disorders". Examples of such disorders are diabetic angiopathy, especially diabetic microangiopathy, e.g.
diabetic gangrene, diabetic retinopathy, diabetic neuropathy, or such as hyperhomocysteinemia, homocysteinuria, pulmonary hypertension, mucoviscidosis, neuro-degenerative disease, ulcus cruris, atrophic gastritis, colitis ulcerosa, or microcirculation disorders occuring after partial resection of stomach and / or bowels;
furthermore re-establishment of blood flow upon insufficient tissue perfusion after revascularisation of large arteries such as after acute MI or Stroke or in peripheral artery disease in addition or following acute antiplatelet therapy to prevent acute reocclusion, e.g. ~as disclosed in WO 98/11896;
similarly conditions where dysfunction is caused by re-perfusion injury after revascularisation or in transplant recipient;
microcirculation disorders caused by inflammatory reactions, such as morbus crohn, colitis ulcerosa or acute respiratory dystress syndrome CARDS);
microcirculation disorders caused by autoimmune diseases, such as autoimmune chronic-active hepatitis (idiopathic hepatitis), primary-biliary cirrhosis or (autoimmune associated) multiple sclerosis;
peripheral microcirculation disorders, such as Raynaud's disease, tinnitus or sudden loss of hearing;
microcirculation disorders associated with increased cell fragmentation, such as tumor diseases or thrombotic-thrombocytopenic purpura (TTP) ;
and nephrosclerosis, prerenal hypertension, haemolytic-uremic syndrome (HUS), arterial hypertension, vascular dementia, Alzheimer's disease, Sudeck's disease, central-veneous thrombosis of the eye, ischemic optic neuropathy, homocystine-induced vasculopathy, ischemic or coronary heart diseases, prevention of myocardial infarction or reinfarction, ... treatment or prevention of atherosclerosis, degenerative diseases of joints such as arthritis.
The indication "NO-dependent microcirculation disorders"
further includes corresponding disorders of the myocardium.
Thus the present invention provides a method for improving the blood supply of the myocardium in a person in need of such treatment, for example in a person suffering from ischemic or coronary heart disease, as well as a method for prevention of myocardial infarction or re-infarction. This in particular after successful reperfusion by mechanical or pharmacological revascularisation and in parallel or after the inhibition of acute rethrombosis / reocclusion by strong inhibitors of platelet aggregation.
Furthermore, treatment of "NO-dependent microcirculation disorders" within the present invention also includes treat-ment or prevention of atherosclerosis by improving perfusion through the vasa vasorum of large vessels.
NO-dependent disorders of the microcirculation can be ap-proached by either increasing the local production of NO or, preferably, by combining the increase of NO with reducing the local destruction of NO.
Preferred is pulmonary hypertension; re-establishment of blood flow upon insufficient tissue perfusion after revascularisa-tion of large arteries such as after acute MI or Stroke or in peripheral artery disease in addition or following acute anti-platelet therapy to prevent acute reocclusion, e.g. as disclo-sed in WO 98/11896; conditions where dysfunction is caused by re-perfusion injury after revasularisation or in transplant recipient; peripheral microcirculation disorders, such as Raynaud's disease, tinnitus or sudden loss of hearing;
_ g -vascular dementia, Alzheimer's disease; homocysteinuria and homocystine-induced vasculopathy;
ischemic or coronary heart diseases; prevention of myocardial infarction or reinfarction; and treatment or prevention of atherosclerosis.
Most preferred indication to be treated according to the present invention is insufficient tissue perfusion after revascularisation of large arteries such as after acute MI or Stroke or re-establishment of blood flow in peripheral artery disease in addition or following acute antiplatelet therapy to prevent acute reocclusion; homocysteinuria and homocystine-induced vasculopathy; and vascular dementia.
It is found that a substance which scavenges free radicals increases the local production of NO. Accordingly, NO-depen-dent microcirculation disorders can be treated according to the present invention by a method of treatment comprising a substance which scavenges free radicals.
Preferred is a substance that scavenges free oxy- and / or peroxi- radicals.
Further preferred is a substance that is membrane bound and scavenges oxy- and peroxy radicals.
Compounds acting as scavengers according to the present invention are, for example, Probucol, Ascorbic acid, Alpha tocopherol, _ g _ Dipyridamole or Mopidamol;
preferred is Dipyridamole and Mopidamol;
most preferred is Dipyridamole.
A said substance is applied optionally in combination with an agent capable of increasing NO production. A compound capable to increase NO production according to the present invention is, for example, Acetylcholine estrogen, or HMG CoA reductase inhibitors such as Lovastatin, Pravastatin, Simvastatin, Fluvastatin, Dalvastatin, Compactin, Mevastatin, HR 780, BMY 22,089, BMY 22,566, SQ 33,600, GR 95,030 or CI 981;
preferred is Lovastatin, Pravastatin, Simvastatin, Fluvastatin, Dalvastatin, Compactin, Mevastatin, HR 780, BMY 22,089, BMY 22,566, SQ 33,600, GR 95,030 or CI 981;
more preferred is Lovastatin, Pravastatin, Simvastatin, Fluvastatin, Dalvastatin, Compactin, Mevastatin.
Preferred is the combination of Mopidamol or even more prefer-red Dipyridamole with an agent selected from the class of HMG
CoA reductase inhibitors. The combination of sub-/or thera-peutical doses of HMG CoA reductase inhibitors known to upre-gulate expression of eNOS (endothelial nitric oxide synthe-tase), which have clinical benefit at lipid lowering doses, with doses of Dipyridamole or Mopidamol, which inhibits destruction of NO.
If the substance which scavenges free radicals is chosen as Dipyridamole or Mopidamol it is of advantage to maintain a plasma level of Dipyridamole or Mopidamol of about 0.2 to 5 umol/L, preferably of about 0.4 to 5 ~mol/L, especially of about 0.5 to 2 umol/L or particularly of about 0.8 to 1.5 umol/L or when combined with HMO CoA reductase inhibitors at 0.2 to 2.0 umol/L. This can be achieved using any of the oral Dipyridamole retard, instant or the parenteral formulations on the market, the retard formulations being preferred, for instance those available under the trademark Persantin°, or, for an optional additional combination therapy with low-dose acetyl salicylic acid (ASA), using those formulations avail-able under the trademark Asasantin° or Aggrenox°. Dipyridamole retard formulations are also disclosed in EP-A-0032562, instant formulations are disclosed in EP-A-0068191 and combinations of ASA with Dipyridamole are disclosed in EP-A-0257344 which are incorporated by reference. In case of Mopidamol also oral retard, instant or a parenteral formu-lations can be used, e.g. those disclosed in GB 1,051,218 or EP-A-0,108,898 which are incorporated by reference, retard formulations being preferred.
Dipyridamole or Mopidamol can be administered orally in a daily dosage of 25 to 450 mg, preferably 50 to 240 mg, most preferred 75 to 200 mg. For long-term treatment it is of advantage to administer repeated doses such as a dose of 25 mg Dipyridamole retard or any other instant release formulation three or four times a day. For parenteral administration Dipy-ridamole could be given in a dosage of 0.5 to 5 mg/kg body weight, preferably 1 to 3.5 mg/kg body weight, during 24 hours as slow i.v. infusion (not faster than 0.2 mg/min).
Dipyridamole {2,6-bis(diethanolamino)-4,8-dipiperidino-pyri-mido[5,'4-d]pyrimidine~, closely related substituted pyrimido-pyrimidines and their preparation have been described in e.g.
U.S. Patent 3,031,450. Further related substituted pyrimido-pyrimidines and their preparation have been described in e.g.
GB 1,051,218, inter alia the compound Mopidamol (2,6-bis-(diethanolamino)-4-piperidinopyrimido[5,4-d]pyrimidine}.
Dipyridamole was introduced as a coronary vasodilator in the early 1960s. It is also well known having platelet aggregation inhibitor properties due to the inhibition of adenosine up-take. However, at doses above the dose range and therapeutically in the Aggrenox~ preparation. Whereas the activity of Dipyridamole and Mopidamol as platelet aggregation inhibitor directly in high concentrations and indirectly through the inhibition of Adenosine reuptake at therapeutic plasma levels is well known it is a new finding that these agents additionally are inhibitors of NO destruction mediated by their capacity to scavange oxi- as well as peroxi radicals while being bound to membranes of cells of the vessel wall.
Previous investigations led to its use as an antithrombotic agent; it soon became the therapy of choice for such applica-tions as stroke prevention, maintaining the patency of corona-ry bypass and valve-replacement, as well as for treatment prior to coronary angioplasty.
Furthermore, the European Stroke Prevention Study 2 (ESPS-2;
J Neurol Sci. 1996; 143: 1-13; Neurology 1998; 51: 17-19) proved that treatment by Dipyridamole alone was as effective as low-dose aspirin in the reduction of stroke risk, and combination therapy with Dipyridamole and aspirin was more than twice as effective as aspirin alone.
Dipyridamole appears to inhibit thrombosis through multiple mechanisms. Early studies showed that it inhibits the uptake of adenosine, which was found to be a potent endogenous anti-thrombotic compound. Dipyridamole was also shown to inhibit cyclic AMP phosphodiesterase, thereby increasing intracellular c-AMP.
Dipyridamole appears to enhance of above-mentioned antithrom-botic mechanisms (CAMP - increase, cGMP- increase) of the vessel wall, in addition to its adenosine-sparing effects. It stimulates prostacyclin production by increasing intracellular levels of cAMP, and it enhances the strongly nitric oxide system by increasing cGMP. It further prevents local fibrin formation.
Dipyridamole also has antioxidant properties (Free Radic.
Biol. Med. 1995; 18: 239-247) that may contribute to its antiatherosclerotic effect. When oxidized, low density lipo-proteins become recognized by the scavenger receptor on macro-phages, which is assumed to be the necessary step in the deve-lopment of atherosclerosis (Ann. Rev. Med. 1992; 43: 219-25).
Dipyridamole has been found to inhibit fibrinogenesis in experimental liver fibrosis (Hepatology 1996; 24: 855-864) and to suppress oxygen radicals and ~proteinuria in experimental animals with aminonucleoside nephropathy (Eur. J. Clin.
Invest. 1998; 28: 877-883; Renal Physiol. 1984; 7: 218-226).
Inhibition of lipid peroxidation also has been observed in human nonneoplastic lung tissue (Gen. Pharmacol. 1996; 27:
855-859) .
Viewed from one aspect the present invention provides a method of treatment of the human or non-human animal body, preferably mammalian body, for treating or preventing NO-dependent micro-circulation disorders or of disease states where such micro-circulation disorders are involved, said method comprising administering to said body an effective amount of a phar-maceutical composition comprising a substance with scavenges fre radicals, according to the invention, optionally in combi-nation with one or more agents capable of increasing NO pro-duction.
A preferred aspect the present invention provides the use of a pyrimido-pyrimidine selected from Dipyridamole, Mopidamol and the pharmaceutically acceptable salts thereof, Dipyridamole being preferred, optionally in combination with one or more agents capable of increasing NO production, preferably selec-ted form the class of HMG CoA-reductase inhibitors, for the manufacture of a pharmaceutical composition for the treatment of the human or non-human animal body, preferably mammalian body, for treating or preventing NO-dependent microcirculation disorders or of disease states where such microcirculation disorders are involved.
Examples Experimentally this condition is tested in animal models show-ing deficiency of microcirculatory function. Animal models used are experimental stroke models in rats and mice as well as in non-rodent animals including non-human primates.
In the stroke models the size of tissue damage after occlusion of an artery feeding a well defined area of the brain tissue is evaluated by histology and non-invasive imaging, measuring the extent of regional perfusion and tissue damage (MRI, CT).
The size of the infarcted tissue is found to be dependent on the capacity of the microcirculatory system to provide blood flow in the periphery under conditions of oxidative and meta-bolic stress. The size of the infarcted tissue is smaller after treatment with a combination of Dipyridamole and pra-vastatin. The same effect can be shown with other agents selected from the class of HMG CoA reductase inhibitors.
Further experiments are carried out with another animal model:
genetically engineered NO Synthetase knock-out mice are used where NO synthetase activity is blocked or partially inhibi-ted, respectively. By employing experimental conditions in such a model under which the NO Synthetase activity is blocked or reduced the effect of Dipyridamole in preventing NO de-struction is investigated and compared with the influence of pravastatin on elevating NO production. Thereby the effect of NO sparing is seen as independent effect in cases were incre-ase of NO production is limited.
The testing in animal models and subsequently in clinical trials with volunteers and patients includes testing of the efficacious dose range according to good clinical practice.
Claims (17)
1. A method of treatment of the human or non-human animal body for treating or preventing NO-dependent microcirculation disorders or of disease states where such microcirculation disorders are involved, said method comprising administering to said body an effective amount of a pharmaceutical compo-sition comprising a substance which scavenges free radicals.
2. A method according to claim 1, in which the substance scavenges free oxi- and/or peroxi-radicals.
3. A method according to claim 1, in which the substance acts as cellular membrane bound substance.
4. A method according to claim 1 in which the substance is a pyrimidino-pyrimidine selected from Dipyridamole, Mopidamol and the pharmaceutically acceptable salts thereof.
5. The method of claim 1, characterized in that the pyrimido-pyrimidine is Dipyridamole.
6. A method according to claim 1 in which the substance is administered in combination with one or more agents capable to increase NO production.
7. The method of claim 1, characterized in that the NO-dependent microcirculation disorder is selected from the group consisting of microcirculation disorders caused by metabolic diseases where vascular damages are involved, such as diabetic angiopathy, especially diabetic micro-angiopathy, e.g. diabetic gangrene, diabetic retinopathy, diabetic neuropathy, or such as hyperhomocysteinemia, homocysteinuria, pulmonary hypertension, mucoviscidosis, neuro-degenerative disease, ulcus cruris, atrophic gastritis, colitis ulcerosa, partial resection of stomach and / or bowels, insufficient tissue perfusion after revascularisation of large arteries such as after acute MI or Stroke or in peripheral artery disease in addition or following acute antiplatelet therapy to prevent acute reocclusion, conditions where dysfunction is caused by re-perfusion injury after revasularisation or in transplant recipient, microcirculation disorders caused by inflammatory reactions, such as morbus crohn, colitis ulcerosa or acute respiratory dystress syndrome (ARDS), microcirculation disorders caused by autoimmune diseases, such as autoimmune chronic-active hepatitis (idiopathic hepatitis), primary-biliary cirrhosis or (autoimmune associated) multiple sclerosis, peripheral microcirculation disorders, such as Raynaud's disease, tinnitus or sudden loss of hearing, microcirculation disorders associated with increased cell fragmentation, such as tumor diseases or thrombotic-thrombocytopenic purpura (TTP), or, as further indications, nephrosclerosis, prerenal hypertension, haemolytic-uremic syndrome (HUS), arterial hypertension, vascular dementia, Alzheimer's disease, Sudeck's disease, central-veneous thrombosis of the eye, ischemic optic neuropathy, homocystine-induced vasculopathy, ischemic or coronary heart diseases, prevention of myocardial infarction or reinfarction, treatment or prevention of atherosclerosis, degenerative diseases of joints such as arthritis.
8. The method of claim 4, characterized in that a plasma level of about 0.2 to 5 µmol/L of the pyrimido-pyrimidine is main-tained.
9. The method of claim 4, characterized in that the pyrimido-pyrimidine is administered using an oral retard, instant or a parenteral formulation.
10. The method of claim 4, characterized in that the pyrimido-pyrimidine is administered orally in a daily dosage of 25 to 450 mg or parenterally in a dosage of 0.5 to 5 mg/kg body weight during 24 hours.
11. The method of claim 6, characterized in that the agent is a HMG CoA reductase inhibitors.
12. The method of claim 7, characterized in that for treatment of a microcirculation disorder associated with increased cell fragmentation a plasma level of Dipyridamole or Mopidamol of about 0.2 to 50 µmol/L is maintained.
13. The use of a substance which scavenges free radicals for the manufacture of a pharmaceutical composition for the treat-ment of the human or non-human animal body for treating or preventing NO-dependent microcirculation disorders or of disease states where such microcirculation disorders are involved.
14. The use of claim 13 in which the substance is a pyrimido-pyrimidine selected from Dipyridamole, Mopidamol and the pharmaceutically acceptable salts thereof.
15. The use of claim 14, characterized in that the pyrimido-pyrimidine is Dipyridamole.
16. The use of claim 13 in which the substance is used in combination with one or more agents capable to increase NO
production.
production.
17. The use of claim 13, characterized in that NO-dependent microcirculation disorder is selected from the group consisting of microcirculation disorders caused by metabolic diseases where vascular damages are involved, such as diabetic angiopathy, especially diabetic micro-angiopathy, e.g. diabetic gangrene, diabetic retinopathy, diabetic neuropathy, or such as hyperhomocysteinemia, homocysteinuria, pulmonary hypertension, mucoviscidosis, neuro-degenerative disease, ulcus cruris, atrophic gastritis, colitis ulcerosa, partial resection of stomach and / or bowels, insufficient tissue perfusion after revascularisation of large arteries such as after acute MI or Stroke or in peripheral artery disease in addition or following acute antiplatelet therapy to prevent acute reocclusion, conditions where dysfunction is caused by re-perfusion injury after revasularisation or in transplant recipient, microcirculation disorders caused by inflammatory reactions, such as morbus crohn, colitis ulcerosa or acute respiratory dystress syndrome (ARDS), microcirculation disorders caused by autoimmune diseases, such as autoimmune chronic-active hepatitis (idiopathic hepatitis), primary-biliary cirrhosis or (autoimmune associated) multiple sclerosis, peripheral microcirculation disorders, such as Raynaud's disease, tinnitus or sudden loss of hearing, microcirculation disorders associated with increased cell fragmentation, such as tumor diseases or thrombotic-thrombocytopenic purpura (TTP), or, as further indications, nephrosclerosis, prerenal hypertension, haemolytic-uremic syndrome (HUS), arterial hypertension, vascular dementia, Alzheimer's disease, Sudeck's disease, central-veneous thrombosis of the eye, ischemic optic neuropathy, homocystine-induced vasculopathy, ischemic or coronary heart diseases, prevention of myocardial infarction or reinfarction, treatment or prevention of atherosclerosis, degenerative diseases of joints such as arthritis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10119680.6 | 2001-04-20 | ||
| DE10119680A DE10119680A1 (en) | 2001-04-20 | 2001-04-20 | Use of scavenger compounds to treat and prevent no-dependent microcirculation disorders |
| PCT/EP2002/004129 WO2002085368A2 (en) | 2001-04-20 | 2002-04-13 | Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2444370A1 true CA2444370A1 (en) | 2002-10-31 |
Family
ID=7682292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002444370A Abandoned CA2444370A1 (en) | 2001-04-20 | 2002-04-13 | Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1389112A2 (en) |
| JP (1) | JP2004525979A (en) |
| AU (1) | AU2002338396B2 (en) |
| CA (1) | CA2444370A1 (en) |
| DE (1) | DE10119680A1 (en) |
| HU (1) | HUP0303754A3 (en) |
| IL (1) | IL158091A0 (en) |
| MX (1) | MXPA03009506A (en) |
| NZ (1) | NZ529115A (en) |
| WO (1) | WO2002085368A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2119459A1 (en) * | 2005-02-11 | 2009-11-18 | NOLabs AB | Treatment of neuropathy involving nitric oxide |
| MD4341C1 (en) * | 2013-11-21 | 2015-11-30 | Ион МЕРЕУЦЭ | Syrup for the treatment of gastric precancerous conditions |
| JP6925272B2 (en) * | 2015-01-28 | 2021-08-25 | リアルイン ライフ サイエンス リミテッド | Compounds that promote PPARγ expression and nuclear translocation and their therapeutic use |
| CN113244395B (en) * | 2020-02-10 | 2024-07-23 | 广州市妇女儿童医疗中心 | Fibrotic disease mechanism and therapeutic agent thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1711892A1 (en) * | 1989-01-06 | 1992-02-15 | Московский медицинский стоматологический институт им.Н.А.Семашко | Method of diabetic angioparhy treatment |
| SU1711894A1 (en) * | 1989-08-08 | 1992-02-15 | Детская Клиническая Больница N1 | Method for treating the decompensated forms of stenosing laryngotracheitis in children |
| IT1239064B (en) * | 1990-05-14 | 1993-09-20 | Fidia Spa | THERAPEUTIC USE OF DIPYRIDAMOL |
| US5270047A (en) * | 1991-11-21 | 1993-12-14 | Kauffman Raymond F | Local delivery of dipyridamole for the treatment of proliferative diseases |
| AU7397094A (en) * | 1993-08-30 | 1995-03-22 | Merck & Co., Inc. | Prevention and treatment of alzheimer's disease |
| US5639482A (en) * | 1993-11-10 | 1997-06-17 | Crary; Ely J. | Composition for control and prevention of diabetic retinopathy |
| AU4988100A (en) * | 1999-05-07 | 2000-11-21 | Brigham And Women's Hospital | Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
-
2001
- 2001-04-20 DE DE10119680A patent/DE10119680A1/en not_active Withdrawn
-
2002
- 2002-04-13 MX MXPA03009506A patent/MXPA03009506A/en active IP Right Grant
- 2002-04-13 CA CA002444370A patent/CA2444370A1/en not_active Abandoned
- 2002-04-13 AU AU2002338396A patent/AU2002338396B2/en not_active Ceased
- 2002-04-13 EP EP02764059A patent/EP1389112A2/en not_active Withdrawn
- 2002-04-13 JP JP2002582941A patent/JP2004525979A/en active Pending
- 2002-04-13 IL IL15809102A patent/IL158091A0/en unknown
- 2002-04-13 NZ NZ529115A patent/NZ529115A/en unknown
- 2002-04-13 WO PCT/EP2002/004129 patent/WO2002085368A2/en active IP Right Grant
- 2002-04-13 HU HU0303754A patent/HUP0303754A3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002085368A2 (en) | 2002-10-31 |
| MXPA03009506A (en) | 2004-02-12 |
| EP1389112A2 (en) | 2004-02-18 |
| DE10119680A1 (en) | 2002-11-14 |
| IL158091A0 (en) | 2004-03-28 |
| HUP0303754A2 (en) | 2004-03-01 |
| NZ529115A (en) | 2005-08-26 |
| AU2002338396B2 (en) | 2007-10-18 |
| JP2004525979A (en) | 2004-08-26 |
| HUP0303754A3 (en) | 2006-02-28 |
| WO2002085368A3 (en) | 2003-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080113934A1 (en) | Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders | |
| Mittal et al. | Nitric oxide modulates hepatic vascular tone in normal rat liver | |
| US20090192123A1 (en) | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of Thrombin and/or by elevated expression of Thrombin receptors | |
| ZA200505956B (en) | Use of dipyridamoi in combination with acetylsalicyclic acid and an angiotensin II antagonist for stroke prevention | |
| US20080076786A1 (en) | Use of radical-scavenging compounds for treatment and prevention of no-dependent microcirculation disorders | |
| CA2444370A1 (en) | Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders | |
| AU2002338396A1 (en) | Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders | |
| US20080275011A1 (en) | Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events | |
| KR20050018330A (en) | Use of dipyridamole, acetylsalicylic acid and an angiotensin II antagonist for treatment and prevention of vascular events | |
| JP2005060359A (en) | Use of dipyridamole, acetyl salicylic acid and angiotensin ii antagonist for treatment and prevention of vascular morbidity | |
| MXPA03007462A (en) | Use of dipyridamole, acetylsalicylic acid and an angiotensinii antagonist for treatment and prevention of vascular events. | |
| TW200522965A (en) | Novel pharmaceutical combination comprising pyrimido-pyrimidine in combination with one other active component for treatment and prevention of fibrin-dependent microcirculation disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |